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months (range, 1.6 to 31.2 months). There was
no correlation between survival and radiotherapy
dose, .sex, pretreatment WHO performance
status and tumor localization.
Our results confirm poor prognosis in
glioblastoma multiforme. New more effective
therapeutic approaches are sorely needed in this
tumour.
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The p53 is transcriptional factor that
enhances the rate of transcription of six or
seven known genes which play important role in
cell cycle regulation. The human p53 protein
contains 393 amino acids and has been divided
structurally and functionally into four domains.
The p53 gene and its protein product have been
studied since it became clear that slightly more
than 50% of human cancers contain mutations
in this gene. A study of mutational spectrum at
the p53 gene are localized predominantly in the
DNA-binding domain of the protein (exons 4-9).
The nature of this changes is most commonly a
missense mutation in one allele followed by a
reduction to homozygosity, producing a faulty
protein. Deletions or chain termination mutations
are more rarely.
Mutations in p53· gene have been also
found in breast cancer in 30-40% of cases. Kind
of these mutations suggest that enviromental
mutagens may play important role in arising of
this type of canceLlt is observed that in West
Poland breast cancer occures more frequently
then in other areas of the country; the highest
numbers of cases are found in GreatPoland still
now for unknown reasons. In this work 48 cases
of breast cancer were studied. 12 different
mutations in p53 were found. This mutations
were then compared with datebase catalogs
containing mutations in p53. Only 3 from 12
found mutations are the same as reported in
datebase. Nine of them were not observed
before what may suggest that specific
mutational spectrum in patients with breast
cancer from GreatPoland exists. Futher studies
involving greater number of cases are needed to
confirm this observation. .
IS ACUTE MUCOSITIS DOSE LIMITING FOR ALTERED FRACTIONATED RADIOTHERAPY?
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There is now a substantial number of studies
on radiotherapy for head and neck cancer using
altered fractionation schedules.
Accumulated dose/week (AD) vs incidence
and severity of acute mucositis
In conventional radiotherapy given in 1.6-2.0
Gy fractions up to total dose of about 70 Gy,
confluent mucositis (CM) is generally reached at
day 22. The threshold for the CM appears to be
around 20 Gy and the CM usually develops
about 9 days after delivering that dose.
However, some studies suggest that the onset
of CM may depend on accumulated dose/week
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and the larger AD is the sooner CM is reached.AII
these observations suggest that the intensity of
acute epithelial reactions, and likely other H-type-
like tissues reflects the balance between the rate
of cell killing by irradiation and the rate of
regeneration of surviving stem cells. Once a
critical level of survival cells has been attained, a
certain type of clinical damage will develop at a
rate only determined by the cellular kinetics of the
tissue. When a peak in the CM is reached, further
stem cell killing can not produce an increase in
intensity of acute reactions, but could be manifest




Analysis of the sets of data of accelerated,
predominantly accelerated and
hyperfractionated radiation treatments shows
that, except with hyperfractionation and short
single course accelerated regimens, the AD is
not constant in consecutive weeks of treatment.
High AD, above 25 Gy is typical for accelerated
treatments when the dose is condensed into a
single course in a short overall treatment time.
Conclusions
1. When fractionation regimens are altered to
achieve a therapeutic gain through an increased
tumour response relative to late normal tissue
response, acute mucosal reactions become
dose limiting in radiotherapy for head and
cancer.
2. Acceptable risk of acute mucositis can be
expected when the Dose-Time Ratio (DTR) is
lower than 2.5 Gy x day -2 and accumulated
dose per week (AD) is less than 12 Gy. Higher
AC can only be considered if it is administered
in no more than 2 consecutive weeks of 5-6
week treatment or 2-3 week split is given
between series of high AD (or DTR).
3. High constant value of the AD (>14 Gy)
during 5-6 weeks of treatment or the AD above
20 Gy and DTR above 10 Gy x day-2 lead to
high risk of persistent confluent mucositis and
consequential late necrosis which may occur
within 4-8 months after treatment.
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We have designed phase 1111 human
melanoma gene therapy clinical protocol. The
aim of the study was to actively immunize HLA-
A1 and/or HLA-A2-positive patients with
melanoma with an admixture of irradiated
autologous tumor cells and allogeneic
melanoma cells genetically engineered to
secrete IL-6 and sIL-6R in order to elicit or
enhance specific and nonspecific anti-
melanoma immune responses to autologous
tumor cells to eradicate distant melanoma
lesions. Irradiation of autologous and allogeneic
tumor cells is a key step in preparation of
cellular vaccine because of two major reasons,
(i) it inhibits cell proliferation which is crucial in
the case of autologous cells which may form a
tumor; (ii) it increases melanoma vaccine
immunogenicity. The aim of the study was to
estimate the optimal dose of ionizing radiation
which will provide sterilization of both
autologous and allogeneic melanoma cells and
will ensure cytokine secretion.
Human melanoma cells (Mich-1) were
transduced with IL-6 and sIL-6R cDNA using
double copy bicistronic retroviral vector. Parental
and transduced cells were seeded at in six-well
tissue culture plates and were irradiated with 10,
47
50, 100 and 200 Gy. Secretion of both
recombinant proteins into culture was analyzed
before and 24, 48,72, 96 hand 6, 7, 10 and 12
days following irradiation. At the same time
adherent cells were enumerated, evaluated for
viability and proliferation. At 24, 48, 72 and 96 h
postirradiation specific IL-6 and sIL-6R mRNA
levels were analyzed.
Irradiation of gene modified cells
inhibited their proliferation in the dose
dependant manner. Dose of 50 Gy sufficiently
affected cell proliferation, however, for safety
reasons we decided to use the dose of 100 Gy
for vaccine preparation. Irradiation did not inhibit
secretion of IL-6 and sIL-6R. In contrary, on a
per cell basis it significantly increased their
secretion which lasted 12 days postirradiation.
Interestingly, we did not observe dose or time
dependent differences in specific mRNA cellular
levels suggesting that increased secretion of
both proteins is regulated not on the
transcriptional but rather on the
posttranscriptional level. Taking all these facts
into account we concluded that irradiation of
tumor cells may provide an effective and safe
approach for gene-modified vaccine
preparation.
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